EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Metabolic Syndrome Among Testicular Cancer Survivors: Long‐Term Follow‐Up of the Veterans Affairs Health System

Dhruv Puri iD, Paul Riviere, Margaret Meagher, Kylie Morgan, Tyler Nelson iD, Kit Yuen, Kshitij Pandit, Nuphat Yodkhunnatham, Jacob Taylor, Daniel Herchenhorn, Tyler Stewart, Juan Javier-Desloges iD und 7 weitere

Cancer Medicine · 2025

DOI: 10.1002/cam4.70858 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Cancer Medicine, 2025. Verfasst von Dhruv Puri und 18 weiteren Autor:innen. Beteiligte Einrichtung: Department of Urology, UC San Diego School of Medicine, La Jolla, California, USA. Hauptthemen laut MEDLINE: Metabolic Syndrome, Testicular Neoplasms, Cancer Survivors, Neoplasms, Germ Cell and Embryonal. Die Arbeit wurde bisher 4-mal zitiert (Crossref) und nennt 33 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

The 5‐year survival rate for patients with testicular germ cell tumors (TC) is excellent. However, these survivors are at an increased risk for metabolic syndrome (MetS), a significant source of morbidity and precursor to cardiovascular disease. This study investigates the incidence of MetS in TC survivors compared to matched controls.

Methods

A retrospective analysis was conducted using the Veterans Affairs national database. The incidence of MetS was compared between 2021 TC survivors and 7595 matched controls. MetS was identified via diagnostic codes and medication use, requiring at least three of five criteria: insulin resistance, dyslipidemia, central obesity, and hypertension. Statistical analysis included chi‐squared and t ‐tests for demographic comparisons, and Cox regression for outcome associations.

Results

TC survivors exhibited a greater prevalence of MetS components than controls, specifically hyperglycemia (28.4%), low HDL levels (59.8%), hypertriglyceridemia (8.0%), and abdominal obesity (27.3%), except for hypertension. Over 5 and 10 years, the cumulative incidence of MetS in TC survivors was 17.0% and 27.8%, compared to 1.9% and 2.8% in controls. Multivariate regression showed an increased incidence of MetS in TC survivors (HR = 19.02, 95% confidence interval [CI]: 16.31–22.19, p < 0.001). Chemotherapy (HR = 1.28, 95% CI: 1.04–1.57, p = 0.017) and increasing age (HR = 1.04, 95% CI: 1.04–1.06, p < 0.001) were associated with a higher risk.

Conclusions

TC survivors have a substantial risk of MetS with a higher occurrence of most MetS components, barring hypertension. Comprehensive metabolic health monitoring is crucial in TC survivorship care. Integrating vigilant screening and preventive strategies can mitigate MetS development in this population.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Metabolic SyndromeTesticular NeoplasmsCancer SurvivorsNeoplasms, Germ Cell and EmbryonalHumansMaleRetrospective StudiesAdultMiddle AgedUnited StatesIncidenceFollow-Up StudiesUnited States Department of Veterans AffairsRisk FactorsPrevalenceCase-Control Studies

Stichwörter der Autor:innen

chemotherapymetabolic syndromeoncology survivorshiptesticular cancer survivors

Autor:innen und Institutionen

  • Department of Urology, UC San Diego School of Medicine, La Jolla, California, USA.
  • Department of Radiation Medicine and Applied Sciences, UC San Diego School of Medicine, La Jolla, California, USA.
  • VA Hospital San Diego, San Diego, California, USA.
  • Department of Urology, UTSW School of Medicine, Dallas, Texas, USA.
  • Division of Hematology and Oncology, Department of Medicine, UC San Diego School of Medicine, La Jolla, California, USA.
  • Department of Urology, Uniformed Services University and Walter Reed National Military Medical Center, Bethesda, Maryland, USA.

ORCID-Profile: Dhruv Puri, Tyler Nelson, Juan Javier-Desloges, Amirali Salmasi

Zitieren

APA

Puri, D., Riviere, P., Meagher, M., Morgan, K., Nelson, T., Yuen, K., Pandit, K., Yodkhunnatham, N., Taylor, J., Herchenhorn, D., Stewart, T., Javier-Desloges, J., Salmasi, A., McKay, R. R., Kern, S. Q., Hofflich, H., Millard, F., Rose, B., & Bagrodia, A. (2025). Metabolic Syndrome Among Testicular Cancer Survivors: Long‐Term Follow‐Up of the Veterans Affairs Health System. Cancer Medicine. https://doi.org/10.1002/cam4.70858

Vancouver

Puri D, Riviere P, Meagher M, Morgan K, Nelson T, Yuen K, et al. Metabolic Syndrome Among Testicular Cancer Survivors: Long‐Term Follow‐Up of the Veterans Affairs Health System. Cancer Medicine. 2025. doi:10.1002/cam4.70858

BibTeX
@article{Puri2025,
  author = {Puri, Dhruv and Riviere, Paul and Meagher, Margaret and Morgan, Kylie and Nelson, Tyler and Yuen, Kit and Pandit, Kshitij and Yodkhunnatham, Nuphat and Taylor, Jacob and Herchenhorn, Daniel and Stewart, Tyler and Javier-Desloges, Juan and Salmasi, Amirali and McKay, Rana R and Kern, Sean Q and Hofflich, Heather and Millard, Frederick and Rose, Brent and Bagrodia, Aditya},
  title = {Metabolic Syndrome Among Testicular Cancer Survivors: Long‐Term Follow‐Up of the Veterans Affairs Health System},
  journal = {Cancer Medicine},
  year = {2025},
  doi = {10.1002/cam4.70858}
}
Kostenlos starten →